心冠通Ⅰ号加抗栓疗法治疗不稳定型心绞痛临床观察

目的:观察心冠通Ⅰ号加低分子肝素和阿司匹林在不稳定型心绞痛中的临床疗效和安全性。方法:使用心冠通Ⅰ号加低分子肝素和阿司匹林治疗不稳定型心绞痛病人21例,并与常规治疗不稳定型心绞痛病人25例进行对照,观察临床症状、静息心电图的改善程度、不良反应发生率。结果:治疗组心绞痛缓解和心电图改善总有效率分别为85.71%和90.48%,不良反应出现率是19.05%;对照组心绞痛缓解和心电图改善总有效率分别为76.00%和84.00%,不良反应出现率是48.00%。两组结果比较,心绞痛缓解率和心电图改善率前者高于后者,治疗组不良反应发生率明显低于对照组且两者之间差异有统计学意义(p<0.05)。结论:心冠通Ⅰ号加低分子肝素和阿司匹林治疗不稳定型心绞痛病人疗效好,不良反应少,安全可靠。

Clinical Observation on Treating Unstable Angina with Xinguantong Ⅰ Decoction plus Antithrombotic Therapy

Objective: To observe the efficacy and safety of Xinguantong I decoction with low molecular weight heparin and aspirin (XLA) in treating unstable angina (UA). Methods: The clinical study was conducted adopting prospective, randomized, double blinded method for 30 days with positive controls. Forty-six UA patients with confirmed diagnosis were divided into the XLA group and the control group, which were treated with XLA and low molecular weight plus aspirin, respectively. The clinical symptoms, rest electrocardiogram and adverse reaction were observed. Results: In the XLA group, the lenitive and electrocardiogram improvement rate were 85.71% and 90.48%, which are better than the rate of 76.00%and84.00% in the control group, respectively. However, the rate of adverse reaction for XLA group is much lower by 28.95 percent than that for control group (P<0.05), which is 48.00 percent. Conclusion: The results of this study suggest that XLA may be helpful to improve the outcome in patients with UA. It could also significantly decrease the adverse reaction rate in traditional antithrombotic therapy for coronary artery disease. Therefore, Xinguantong I decoction is a pure Chinese herbal compound preparation that is worth further deep research and development.